• Kimball Electronics outlined the acquisition of Helvoet Polymer Technologies, a Europe- and India-based medical CDMO focused on microfluidics, diagnostics, drug delivery.
• Purchase price set at EUR 90 million, or about $103 million; valuation at about 9x expected adjusted EBITDA in calendar 2026.
• Helvoet generated about $56 million revenue in calendar 2025; EBITDA margin in the mid-teens; about 70% of revenue tied to medical end markets.
• Deal expected to be accretive to fiscal 2027 adjusted earnings; Kimball projected low double-digit sales growth in its medical vertical.
• Funding to come from cash and existing credit lines; leverage profile expected to remain in line with capital allocation priorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kimball Electronics Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.